Author(s)

Seda Yilmaz¹, Özcan Çeneli²

¹Department of Internal Medicine, Clinic of Hematology, Konya City Hospital, Konya, Turkey.
²Department of Hematology, Necmettin Erbakan University, Konya, Turkey.

Objective: Acute myeloid leukemia (AML) is a heterogeneous, hematologic malignancy at which short survival may be seen. Our study aims to evaluate the effect of the neutrophil-to-lymphocyte ratio (NLR) on the course of the disease, response to therapy, and overall survival (OS). Materials and Methods: A total of 124 patients followed-up with the diagnosis of AML from 2016 to 2019 were retrospectively examined. Results: 69 of the cases (55.6%) were men and 55 (44.3%) were women. The average age at the time of diagnosis was 53.44 ± 30.3 years old. We determined the NLR as median 0.46 (0.16 - 1.1). In AML, 69 patients were responsive to the induction regimen (57.9%) while 46 patients were unresponsive (37.8%). 5 patients died before completing the regimen. D-dimer was found to be higher and fibrinogen was found to be lower in the responsive group. Lower OS was observed in cases of >60 years of age, male gender, non-APL AML, high NLR, and recurrence at diagnosis. Recurrences were detected in 23 patients (18.5%) and the median time to the recurrence was 416 (236 - 639) days. Fibrinogen level and the bone marrow blast ratio at the time of application were determined to be associated with recurrence. The median follow-up time was 856 (143 - 1276) days. Final condition analysis reveals that 74 patients (59.6%) are alive. Conclusion: We determined in our study that the NLR is effective on survival. Medical literature on this subject is scanty and prospective studies with large patient groups are needed.

Acute Myeloid Leukemia, Neutrophil to Lymphocyte Ratio, Prognosis, Survival

Yilmaz, S. and Çeneli, Ö. (2023) Prognostic Value of Neutrophil to Lymphocyte Ratio in Acute Myeloid Leukemia. Open Journal of Internal Medicine, 13, 131-138. doi: 10.4236/ojim.2023.133015.